List of Excipients in Branded Drug TRADJENTA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Cardinal Health 107 LLC	TRADJENTA	linagliptin	55154-0410	COPOVIDONE K25-31
Cardinal Health 107 LLC	TRADJENTA	linagliptin	55154-0410	FERRIC OXIDE RED
Cardinal Health 107 LLC	TRADJENTA	linagliptin	55154-0410	HYPROMELLOSE
Cardinal Health 107 LLC	TRADJENTA	linagliptin	55154-0410	MAGNESIUM STEARATE
Cardinal Health 107 LLC	TRADJENTA	linagliptin	55154-0410	MANNITOL
Cardinal Health 107 LLC	TRADJENTA	linagliptin	55154-0410	POLYETHYLENE GLYCOL

Tradjenta Excipient Strategy and Commercial Opportunities for Linagliptin

Last updated: August 26, 2026

Tradjenta is a 5 mg immediate-release linagliptin tablet marketed by Boehringer Ingelheim and Eli Lilly. Its commercial excipient profile is relatively simple: mannitol, pregelatinized starch, copovidone, magnesium stearate, and a conventional film-coating system. The strongest commercial opportunities are generic excipient substitution, direct-compression optimization, fixed-dose combination development, pediatric and orally disintegrating formats, and differentiated manufacturing platforms.

The core product is no longer protected primarily by the original composition patent. Commercial barriers now depend on formulation performance, regulatory equivalence, combination-product complexity, supply reliability, and any remaining patent claims covering crystalline forms, formulations, or methods of use.

What is Tradjenta and how is linagliptin formulated?

Tradjenta contains linagliptin, a selective dipeptidyl peptidase-4 inhibitor used for type 2 diabetes. The approved dose is 5 mg once daily, with no dose adjustment recommended for renal or hepatic impairment [1].

What excipients are used in Tradjenta tablets?

The U.S. prescribing information identifies the following inactive ingredients:

Component	Function in the tablet
Mannitol	Diluent, mouthfeel modifier, compression aid
Pregelatinized starch	Binder and disintegrant
Copovidone	Binder and granulation or compression aid
Magnesium stearate	Lubricant
Hypromellose	Film-forming coating polymer
Titanium dioxide	Opacifier and pigment
Talc	Anti-tacking and coating aid
Red iron oxide	Colorant

The tablet is an immediate-release, film-coated dosage form. Its low active-ingredient load creates a substantial excipient-to-drug ratio. That ratio makes blend uniformity, segregation control, lubrication, and content uniformity important development variables.

What are the key physical and chemical attributes of linagliptin?

Linagliptin is a potent, low-dose small molecule. The commercial product therefore requires tight control over:

• Active pharmaceutical ingredient distribution through the powder blend.
• Particle-size compatibility between linagliptin and the diluent system.
• Segregation during transfer and tablet compression.
• Lubricant mixing time and magnesium stearate coverage.
• Dissolution after coating.
• Solid-state form and polymorphic stability.
• Moisture exposure during granulation, coating, and storage.

The low dose supports the use of direct compression or dry granulation if the active substance has suitable flow and compressibility. Wet granulation can improve content uniformity but adds process complexity and moisture exposure.

Which excipient strategies are most relevant to generic Tradjenta?

Generic developers can pursue two regulatory strategies: replicate the reference formulation closely or use a functionally different excipient system that demonstrates pharmaceutical equivalence and bioequivalence.

Strategy 1: Reference-like excipient substitution

A near-copy approach would retain:

• A polyol diluent such as mannitol.
• Pregelatinized starch or an equivalent starch-based disintegrant.
• Copovidone or another compendial binder.
• Magnesium stearate.
• A conventional hypromellose film coat.

This approach reduces development risk because the formulation architecture is already clinically established. The principal opportunity is cost reduction through second-source excipients, regional supply, improved particle-size grades, and more efficient processing.

Strategy 2: Direct-compression reformulation

A generic manufacturer could replace the reference excipient system with a co-processed direct-compression platform. Potential alternatives include:

• Microcrystalline cellulose combined with mannitol.
• Spray-dried mannitol.
• Co-processed cellulose and starch.
• Lactose-based direct-compression blends.
• Low-substituted hydroxypropyl cellulose as a disintegrant.
• Crospovidone or sodium starch glycolate where dissolution permits.

The development target is not simply hardness. The formulation must achieve acceptable friability, rapid disintegration, dissolution similarity, content uniformity, and stability across commercial-scale compression speeds.

For linagliptin, a co-processed excipient can have commercial value if it reduces the number of raw materials, improves low-dose blend uniformity, or permits high-speed tableting without wet granulation.

Strategy 3: Dry granulation

Roller compaction can improve flow and reduce segregation in a low-dose formulation. It also avoids water and elevated drying temperatures. The principal risks are:

• Recompaction-induced hardness changes.
• Slower dissolution from excessive granule density.
• Fines generation during milling.
• Active-content segregation after granule sizing.
• Increased tablet weight or compression force.

A dry-granulated linagliptin tablet could be attractive for manufacturers operating in regions where wet-granulation capacity is constrained or where solvent and energy reduction are commercial priorities.

Strategy 4: Wet granulation

Wet granulation remains technically viable when the active substance has poor flow or when the target dose requires a highly uniform blend. Copovidone or povidone can provide binding capacity, while starch-based disintegrants can restore rapid tablet breakup.

The principal commercial disadvantage is process cost. Wet granulation requires controlled addition of liquid, drying, endpoint determination, milling, and additional in-process testing. It may also create a more difficult stability profile if residual moisture affects the active substance or excipient interaction.

What formulations are protected by Tradjenta-related patents?

The original linagliptin composition patent was U.S. Patent No. 7,407,955, assigned to Boehringer Ingelheim International GmbH and directed to xanthine compounds, including linagliptin-related subject matter. The patent had an original term extending into 2022, subject to applicable patent-term adjustment or extension [2].

What is the Orange Book status of Tradjenta?

Tradjenta was approved by the FDA under NDA 201280 in May 2011 [1,3]. Orange Book-listed patents historically included patent protection associated with the active ingredient and approved uses. The original composition protection has expired, while later patents and regulatory exclusivities must be assessed separately through the current Orange Book and FDA patent-listing records [3].

The commercial implication is that the key barrier for a conventional 5 mg linagliptin tablet is no longer the existence of the original active-ingredient patent. Remaining barriers can include:

• Listed formulation patents.
• Method-of-use patents.
• Patents covering crystalline or solid-state forms.
• Combination-product patents.
• Pediatric regulatory exclusivity.
• Litigation settlements that delay commercial launch.

Patent families outside the Orange Book can still affect supply-chain planning, manufacturing processes, or non-U.S. launches, even when they do not block an ANDA directly.

What is the patent strength of the Tradjenta formulation?

The formulation estate is weaker than an estate built around a complex controlled-release system, device, lipid formulation, or biologic delivery platform. Tradjenta is an immediate-release tablet using widely available excipients.

Its residual formulation risk is therefore concentrated in claim scope and regulatory interpretation. A patent that claims a specific ratio, particle-size distribution, manufacturing sequence, crystalline form, or dissolution profile may be avoidable through a carefully designed generic process. Broad claims covering linagliptin itself are less relevant after expiration of the original composition protection.

When does Tradjenta lose exclusivity?

Tradjenta’s principal U.S. market exclusivity ended after the expiration of the original linagliptin patent term and any applicable regulatory extensions. FDA approval in 2011 also created a period of new-chemical-entity exclusivity, which expired before the present generic-development period [1,3].

What is the practical generic-entry timeline?

Milestone	Commercial significance
May 2011	FDA approval of Tradjenta
2016	End of five-year new-chemical-entity exclusivity, subject to FDA records
August 2022	Approximate expiration period for the principal U.S. linagliptin composition patent
2022 onward	Greater opportunity for ANDA development, subject to listed patents and litigation
Post-expiration	Market entry depends on FDA approval, Paragraph IV outcomes, settlements, and manufacturing readiness

The exact launch date for any generic depends on the applicant’s certification, patent litigation, settlement terms, regulatory review, and commercial strategy. Patent expiry alone does not establish a specific launch date.

Which companies are challenging Tradjenta patents?

Generic companies seeking approval for linagliptin tablets can file ANDAs with Paragraph IV certifications against listed patents. A Paragraph IV certification states that the applicant believes a listed patent is invalid, unenforceable, or will not be infringed by the proposed product under the applicant’s use.

The relevant parties are:

• Boehringer Ingelheim, the principal originator and patent-holder entity.
• Eli Lilly, the original U.S. commercial partner.
• ANDA applicants seeking approval for linagliptin tablets.
• Contract manufacturers and API suppliers supporting those applicants.

A current company-by-company litigation roster requires review of the FDA Orange Book, FDA Paragraph IV notices, district-court dockets, and settlement filings. Public records should be checked separately for each ANDA because patent challenges can concern different patents and different proposed labeling.

What FDA regulatory pathway applies to generic linagliptin?

A conventional generic Tradjenta tablet would normally proceed through an ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference-listed drug [4].

What does pharmaceutical equivalence require?

The generic product generally must match the reference drug in:

• Active ingredient.
• Strength.
• Dosage form.
• Route of administration.
• Labeling, subject to permitted differences.
• Quality and performance standards.

Different inactive ingredients may be acceptable if they do not affect safety, efficacy, manufacturability, or bioequivalence.

How do excipients affect bioequivalence?

For an immediate-release low-dose tablet, excipients can change:

• Wetting and disintegration.
• Dissolution rate.
• Drug release across pH conditions.
• Gastric emptying behavior.
• Powder compactibility.
• Tablet porosity.
• Stability and degradation.

A formulation that dissolves rapidly under one test condition may diverge under another. Developers should evaluate dissolution across multiple pH media and apply discriminatory methods capable of detecting meaningful formulation differences.

What commercial opportunities exist for Tradjenta excipients?

Co-processed excipient platforms

The largest broad-market opportunity is a co-processed excipient blend designed for low-dose direct compression. A supplier could position such a platform around:

• Improved content uniformity.
• Reduced segregation.
• Lower lubricant sensitivity.
• Higher tablet throughput.
• Lower compression-force variability.
• Shorter development time.

The value proposition is strongest when the excipient platform can support both linagliptin monotherapy and linagliptin fixed-dose combinations.

Film-coating systems

Ready-to-use film-coating premixes can reduce color-matching, dispersion, and process-development work. Commercial targets include:

• Consistent red coloration.
• Lower coating weight.
• Faster drying.
• Reduced tablet twinning and sticking.
• Improved visual differentiation between strengths or products.

A coating supplier could also offer titanium-dioxide-free systems for markets with formulation restrictions or customer-specific environmental requirements.

Low-dose uniformity solutions

Linagliptin’s 5 mg strength creates an opportunity for excipient suppliers with:

• Engineered particle-size distributions.
• High-purity spray-dried diluents.
• Ordered-mixture technologies.
• Surface-modified carriers.
• Continuous blending systems.
• Statistical process-control tools.

The commercial advantage is greatest for manufacturers seeking fewer blend-uniformity failures and lower sampling burdens.

Pediatric and orally disintegrating formulations

A pediatric linagliptin product could use mannitol, crospovidone, flavoring systems, and taste-masking technologies. Potential formats include:

• Orally disintegrating tablets.
• Mini-tablets.
• Sprinkle granules.
• Dispersible tablets.
• Oral powder sachets.

These products would require regulatory and clinical support beyond a standard ANDA if they differ materially from the reference product. They could also face patent or regulatory barriers depending on the target indication and labeling.

Fixed-dose combination products

Linagliptin is already used in combination products with metformin and other antidiabetic agents. Combination tablets create larger excipient opportunities because they require simultaneous control of:

• Different dose loads.
• Different particle sizes.
• Moisture sensitivity.
• API-excipient compatibility.
• Layering or bilayer-tablet behavior.
• Immediate-release versus extended-release components.

Relevant commercial products include Jentadueto, Glyxambi, and Trijardy XR, although each has a separate formulation and patent analysis [5-7].

How does Tradjenta compare with competing DPP-4 inhibitors?

Product	Active ingredient	Typical dosage form	Excipient opportunity
Tradjenta	Linagliptin	5 mg immediate-release tablet	Low-dose uniformity, direct compression, film coating
Januvia	Sitagliptin	Immediate-release tablet	High-volume generic excipient demand, coating and compression
Onglyza	Saxagliptin	Immediate-release tablet	Low-dose formulation and solid-state control
Nesina	Alogliptin	Immediate-release tablet	Low-dose blending and combination products
Galvus	Vildagliptin	Immediate-release tablet	Regional generic formulation and combination opportunities

Linagliptin has a distinctive commercial advantage in renal dosing because the approved label does not require dose adjustment for renal impairment. That supports continued demand for a single-strength 5 mg presentation, which simplifies manufacturing and distribution relative to products requiring multiple renal-dose strengths [1].

What manufacturing and intellectual-property barriers affect commercial entry?

The active ingredient is only one part of the entry equation. Commercial risk also arises from:

• API impurity control.
• Polymorph or crystalline-form selection.
• Particle-size reproducibility.
• Low-dose blend uniformity.
• Tablet coating consistency.
• Dissolution similarity.
• Stability under high humidity.
• Supplier qualification.
• Regional excipient compendial requirements.
• Patent claims covering manufacturing methods.

An excipient change can create a non-infringing design-around, but it can also introduce a new regulatory risk if the change affects dissolution or bioequivalence. The best commercial formulation is therefore not necessarily the closest copy. It is the formulation that combines robust manufacturing with a clear patent position and predictable ANDA performance.

What generic launch scenarios exist for Tradjenta?

Early launch after patent settlement

An ANDA applicant may secure a launch date before the full end of all listed patent terms through a settlement with the originator. The agreement may include a delayed entry date, supply terms, or other commercial provisions. Settlement terms must be reviewed for each applicant.

At-risk launch

A manufacturer may launch before final resolution of patent litigation. This exposes the company to potential damages, injunctions, and supply disruption. At-risk entry is more likely when the remaining patent claims appear narrow or vulnerable.

Post-expiry launch

A post-expiry launch has lower patent risk but may face rapid price erosion. Excipient cost, manufacturing yield, packaging efficiency, and distribution scale become more important.

Authorized generic or supply arrangement

The originator or a partner may use an authorized generic, contract supply, or licensing arrangement to retain commercial participation after patent expiry. Such arrangements can affect price competition and API demand.

What is the biosimilar risk for Tradjenta?

There is no biosimilar pathway for Tradjenta because linagliptin is a chemically synthesized small molecule, not a biologic. Competitive risk comes from ANDA-approved generics, authorized generics, fixed-dose combinations, and therapeutic substitution within the DPP-4 inhibitor class.

The absence of biosimilar complexity lowers the regulatory barrier compared with biologic products. It also increases the likelihood that price competition will focus on formulation cost, manufacturing scale, API sourcing, and launch timing.

What is the revenue exposure to generic linagliptin?

Revenue exposure depends on the geographic market, payer mix, combination-product sales, patent settlements, and the speed of generic substitution. The main erosion mechanism is usually formulary-driven price compression after multiple generic suppliers enter.

Boehringer Ingelheim and Eli Lilly have reported diabetes-product revenue through corporate financial disclosures, but Tradjenta-specific sales may not always be separately disclosed. Commercial analysis should distinguish:

• Tradjenta monotherapy revenue.
• Jentadueto revenue.
• Glyxambi revenue.
• Trijardy XR revenue.
• Regional sales outside the United States.
• Contract or partner revenue.

The excipient opportunity can remain attractive even after branded revenue declines because generic volume may increase while unit price falls.

Key Takeaways

• Tradjenta is a 5 mg immediate-release linagliptin tablet with a relatively simple excipient system.
• The principal excipients are mannitol, pregelatinized starch, copovidone, magnesium stearate, and a hypromellose-based film coat.
• The strongest generic formulation opportunities involve direct compression, co-processed excipients, low-dose blend uniformity, dry granulation, and ready-to-use coating systems.
• The original linagliptin composition patent has expired or passed its principal term, shifting competitive focus to later patents, ANDA certifications, settlements, and manufacturing execution.
• Tradjenta has no biosimilar risk. Generic substitution is the central post-exclusivity threat.
• Fixed-dose combinations create a larger and more technically demanding excipient market than the monotherapy tablet.
• Excipient suppliers can compete through improved flow, content uniformity, compression speed, coating efficiency, stability, and regulatory support.

FAQs about Tradjenta excipient strategy

Can a generic linagliptin tablet use lactose instead of mannitol?

Yes. A generic applicant may use a different diluent if the product meets pharmaceutical-equivalence, quality, stability, dissolution, and bioequivalence requirements.

Is mannitol essential to Tradjenta performance?

No. Mannitol is part of the reference formulation, but it is not inherently required for linagliptin tablets. Its replacement would require formulation and regulatory justification.

Can linagliptin be developed as an orally disintegrating tablet?

Yes, but an orally disintegrating tablet would require a formulation designed for rapid disintegration, acceptable taste, mechanical strength, and appropriate regulatory support.

Are Tradjenta and Jentadueto protected by the same patents?

Not necessarily. Jentadueto combines linagliptin with metformin and may have separate formulation, combination, and method-of-use patents.

Which excipient is most commercially important for generic linagliptin?

A multifunctional diluent or co-processed excipient that improves low-dose content uniformity and direct compression has the broadest commercial potential.

References

1. U.S. Food and Drug Administration. (2024). Tradjenta (linagliptin) tablets: U.S. prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc.

2. U.S. Patent No. 7,407,955. (2008). Xanthine compounds and pharmaceutical compositions containing them. U.S. Patent and Trademark Office.

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2014). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA.

5. U.S. Food and Drug Administration. (2024). Jentadueto (linagliptin and metformin hydrochloride) prescribing information. FDA.

6. U.S. Food and Drug Administration. (2024). Glyxambi (empagliflozin and linagliptin) prescribing information. FDA.

7. U.S. Food and Drug Administration. (2024). Trijardy XR (empagliflozin, linagliptin, and metformin hydrochloride extended-release) prescribing information. FDA.